With the call of the "Healthy China Strategy" and the "Community of Shared Future for Human Health", Chinese IVD companies have more opportunities for innovation and development. Wuhan EasyDiagnosis Biomedicine Co., Ltd. has developed rapidly since its establishment. On October 24, EasyDiagnosis Bio-Shanghai R&D Center was formally established. Since then, the company has established a dual-center Wuhan + Shanghai R&D structure.

Image credit:  Wuhan EasyDiagnosis Biomedicine Co., Ltd.

Hzymes Biotechnology Co.,Ltd. has established a multidisciplinary R&D and production system for genetic engineering and synthetic biology in several years. Based on five special enzyme creation technology platforms, it provides customers with in vitro diagnostic reagents such as biochemical testing, immunological testing, molecular diagnosis and core raw materials. At the same time, the research and development and large-scale production of core enzyme materials related to mRNA drugs, nucleotides, and cap structures will be completed.

Based on the above business model, Hzymes Biotechnology needs to gather high-end R&D talents to get close to customer needs. Therefore, in 2020, the company will set up a management R&D and marketing center in Shanghai.

Image Credit: Hzymes Biotechnology Co.,Ltd.